BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients

Trial Profile

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOOM
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Results (n=2483) of post-hoc analysis assessing changes in liver enzymes in patients treated with Lorcaserin for obesity from three pivotal trials (BLOSSOM, BLOOM and BLOOM-DM), presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 17 Sep 2017 Results of a pooled analysis from BLOOM & BLOSSOM trials (n=5658) presented at the Council on Hypertension Scientific Session 2017
    • 17 Sep 2017 Results of a pooled cohort analysis from BLOOM, BLOSSOM, BLOOM-DM trials presented at the Council on Hypertension Scientific Session 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top